CLDN3 and ovarian carcinoma: The ongoing research into the regulation and function of CLDN3 in ovarian cancer not only deepens our understanding of the disease’s molecular underpinnings but also paves the way for novel, targeted immunotherapies that could significantly impact patient outcomes in ovarian cancer, a malignancy notorious for its resistance to conventional treatments [53, 56, 57].